Close Menu

NEW YORK – In a Phase I/II trial of Novartis' PI3 kinase inhibitor alpelisib (Piqray) combined with an aromatase inhibitor, investigators observed that only 52 percent of the 44 hormone receptor-positive breast cancer patients enrolled in the trial derived a clinical benefit from treatment. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.